Boehringer Ingelheim Pharmaceuticals, Inc.

Rhone-poulenc Rorer Pharmaceuticals Inc.

Rorer Pharmaceutical Corporation

Usv Pharmaceutical Corporation

Aventis Pharma Limited

Boehringer Ingelheim International Gmbh

Rhone Poulenc Rorer

Boehringer Ingelheim Pharma Gmbh & Co Kg

John R Regan

Pier Francesco Cirillo

Kent W Neuenschwander

Eugene R Hickey

John T Suh

Neil Moss

Jeffrey N Barton

Thomas A Gilmore

Abdelhakim Hammach

Jerry W Skiles

Paul R Menard

Stevan Wakefield Djuric

David S Thomson

John Robert Proudfoot

Anthony C Scotese

Daniel Kuzmich

Michael N Chang

Steffen Breitfelder

Alan David Swinamer

Daniel Gerard McGarry

Gregory Bernard Poli

Edward S Neiss

Paul Joseph Cox

David John Aldous

Lin-Hua Zhang

Kevin Joseph Moriarty

Christopher Hulme

Rose Mappilakunnel Mathew

Fu-Chih Huang

Robert A Groneberg

Howard Jones

John J Piwinski

Donald E Kuhla

Daniel R Goldberg

Hidenori Takahashi

Charles Lawrence Cywin

Peter Charles Astles

Darren DiSalvo

Jack Newman

John W Ullrich

Christopher Pargellis

Daniel G McGarry

Schmuel Ben-Sasson

Joseph G Bruno

Shelley Bower

Doris Riether

Renee M Zindell

Sanxing Sun

Thomas Martin Kirrane, Jr

Usha R Patel

Younes Bekkali

Rajashekhar Betageri

Zhulin Tan

Victor Marc Kamhi

Jennifer A Kowalski

Rajiv Sharma

Rajashehar Betageri

Mark Stephen Ralph

Paul S Riska

Thomas M Kirrane

Thomas Wai-Ho Lee

James J Mencel

Benedict J Kosmider

Pier Francesco

Kristen Mueller

Michele Tsang

Monica H Moriak

Brian Andrew Walter

Roger Dinallo

Josehp G Bruno

Kent E Neuenschwander

Francis A Volz

Paul Menard

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Sulfone compounds which modulate the CB2 receptor

Compounds of Formula (I) wherein R, R, R, R, R, R, and Rare as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

Compounds of Formula (I) wherein R, R, R, R, R, R, and X are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and pharmaceutically acceptable salts of the compounds of formula (I) and N-oxides thereof, Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmnaceutical compositions comprising compoundS of formula (I), their phatmaceUtical use and methods for their preparation.

Substituted azabicyclic compounds

Disclosed are methods of treating acute and chronic inflammation in the lung caused by inhalation of smoke, endometriosis, Behcet's disease, uveitis, ankylosing spondylitis, pancreatitis, cancer, Lyme disease, sepsis, chronic obstructive pulmonary disease, traumatic arthritis, congestive heart failure and restenosis following percutaneous transluminal coronary angioplasty, known to be cytokine mediated, using aromatic heterocyclic compounds described in WO 00/55139.

Methods of treating cytokine mediated diseases

Disclosed are 1,4-disubstituted benzo-fused urea compounds of formula (I):wherein Ar, X, A, L, and Q of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

1,4-benzofused urea compounds useful in treating cytokine mediated diseases

Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar,Ar,L,Q and X are described herein.

Disclosed are compounds useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Compounds useful as anti-inflammatory agents

1,4-Disubstituted benzo-fused urea compounds

Disclosed are novel 1,4-disubstituted benzo-fused compounds wherein G, X, L, Q, n and Y are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

1,4-Disubstituted benzo-fused compounds

Disclosed are novel aromatic compounds of the formula(I) described herein, wherein G, E, W, Ar, X, Y and Z are disclosed herein. The compounds are useful for treating cytokine mediated diseases or conditions such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.

Carbamate and oxamide compounds

Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.

Disclosed are novel aromatic compounds of the formula(I) wherein G, E, W, Ar, X, Y and Z. The compounds are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.

Growing community of inventors

Larchmont, NY, United States of America

John R Regan